Success Story: From Preventive Cardiology Research to NIW Approval for a Cardiovascular Medicine Expert
Client’s Testimonial:
"Thanks so much for the support during the process,”
On May 1st, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Research Fellow in the Field of Cardiovascular Medicine (Approval Notice).
General Field: VCardiovascular Medicine
Position at the Time of Case Filing: Research Fellow
Country of Origin: Egypt
State of Residence at the Time of Filing: Arizona
Approval Notice Date: May 1st, 2026
Processing Time: 1 month, 25 days (Premium Processing Requested)
Case Summary:
Not every cardiovascular case turns on emergency treatment. Some of the most important work happens earlier, before a patient reaches crisis, when risk can still be recognized, treatment can still be adjusted, and disease progression can still be slowed. That preventive focus was central to this NIW approval.
The petitioner’s work integrates several tools that are often discussed separately but rarely framed as one coordinated strategy: pharmacotherapy, biomarkers, AI-enhanced electrocardiography, and cardiac imaging. North America Immigration Law Group (Chen Immigration Law Associates) presented the case by showing that this combination could help clinicians identify high-risk patients earlier, improve treatment selection, and make cardiovascular prevention more scalable. The petition tied this work to a practical national need as the United States faces a growing burden from chronic cardiovascular disease and the evolving nature of acute cardiac events.
To underscore the practical value of the case, the petition highlighted how deeply the research is rooted in real-world clinical decision-making. By detailing successful implementations of AI-assisted diagnostic tools and advanced monitoring protocols for complex conditions, we framed the proposed endeavor as a concrete, evidence-based continuation of ongoing efforts to make precision medicine more accurate and actionable.
We documented 54 peer-reviewed journal articles, 11 abstracts, 830 citations, and at least 56 completed peer reviews. His publications appeared in leading journals, with multiple papers ranking among the top one percent or top 10% of most-cited clinical medicine articles for their publication years. Furthermore, his work had already been incorporated into statements, guidelines, and position papers from major professional and public-health organizations.
We were proud to help secure this NIW approval for a researcher whose work strengthens preventive cardiology by combining clinical evidence with AI tools that can improve earlier detection, smarter risk assessment, and better long-term cardiovascular care in the United States.